CPL207280
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes[1][2].
Product Specifications
CAS Number
2361497-72-3
UNSPSC
12352005
Target
Free Fatty Acid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/cpl207280.html
Purity
98.72
Solubility
10 mM in DMSO
Smiles
OC(C[C@@H](C1=CC=C(C=C1)OC/C(C)=C(C)/C)C#CC)=O
Molecular Formula
C18H22O3
Molecular Weight
286.37
References & Citations
[1]Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810.|[2]Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CAU25637-01 100 µL
Phospholipase C Beta 3, Phosphoinositide Specific (PLCb3) Polyclonal Antibody
Sign In for Pricing
View Details